Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients From 1 Year to <18 Years of Age With Juvenile Idiopathic Arthritis (JIA)

NCT03773965 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT03773965
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03773965 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients From 1 Year to <18 Years of Age With Juvenile Idiopathic Arthritis (JIA)
Lead sponsor
Eli Lilly and Company
Phase
Phase 3
Overall status
Recruiting
Start date
April 5, 2019
Completion date
July 31, 2031
Enrollment
190 (estimated)
Sites
78

Conditions

As the registry lists them; a condition with its own page is linked.

juvenile idiopathic arthritis